<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0019296"><a href="http://purl.obolibrary.org/obo/MONDO_0019296">MONDO:0019296</a></h3>
<p><strong>Label:</strong> subcutaneous tissue disease</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0019599">MONDO:0019599</a> (primary lipodystrophy), <a href="http://purl.obolibrary.org/obo/MONDO_0016584">MONDO:0016584</a> (mandibuloacral dysplasia), <a href="http://purl.obolibrary.org/obo/MONDO_0020087">MONDO:0020087</a> (genetic lipodystrophy), <a href="http://purl.obolibrary.org/obo/MONDO_0018883">MONDO:0018883</a> (Berardinelli-Seip congenital lipodystrophy), <a href="http://purl.obolibrary.org/obo/MONDO_0020088">MONDO:0020088</a> (familial partial lipodystrophy), <a href="http://purl.obolibrary.org/obo/MONDO_0007908">MONDO:0007908</a> (multiple symmetric lipomatosis), <a href="http://purl.obolibrary.org/obo/MONDO_0020089">MONDO:0020089</a> (acquired lipodystrophy), <a href="http://purl.obolibrary.org/obo/MONDO_0019194">MONDO:0019194</a> (localized lipodystrophy),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://purl.obolibrary.org/obo/OMIM_604367">OMIM:604367</a>, <a href="http://purl.obolibrary.org/obo/OMIM_608600">OMIM:608600</a>, <a href="http://purl.obolibrary.org/obo/OMIM_608612">OMIM:608612</a>, <a href="http://purl.obolibrary.org/obo/OMIM_151660">OMIM:151660</a>, <a href="http://purl.obolibrary.org/obo/OMIM_269700">OMIM:269700</a>, <a href="http://purl.obolibrary.org/obo/OMIM_151800">OMIM:151800</a>, <a href="http://www.orpha.net/ORDO/Orphanet_2398">Orphanet:2398</a>, <a href="http://purl.obolibrary.org/obo/OMIM_248370">OMIM:248370</a>, <a href="http://purl.obolibrary.org/obo/OMIM_615238">OMIM:615238</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98305">Orphanet:98305</a>, <a href="http://purl.obolibrary.org/obo/OMIM_613877">OMIM:613877</a>, <a href="http://www.orpha.net/ORDO/Orphanet_528">Orphanet:528</a>, <a href="http://www.orpha.net/ORDO/Orphanet_79088">Orphanet:79088</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98306">Orphanet:98306</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98307">Orphanet:98307</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612526">OMIM:612526</a>, <a href="http://purl.obolibrary.org/obo/OMIM_608594">OMIM:608594</a>, <a href="http://www.orpha.net/ORDO/Orphanet_90970">Orphanet:90970</a>, <a href="http://www.orpha.net/ORDO/Orphanet_2457">Orphanet:2457</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.82%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011121">HP:0011121</a> (Abnormality of skin morphology) 76.82%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001574">HP:0001574</a> (Abnormality of the integument) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.82%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000951">HP:0000951</a> (Abnormality of the skin) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.82%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003119">HP:0003119</a> (Abnormality of lipid metabolism) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011368">HP:0011368</a> (Epidermal thickening) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011368">HP:0011368</a> (Epidermal thickening) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011014">HP:0011014</a> (Abnormal glucose homeostasis) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011013">HP:0011013</a> (Abnormality of carbohydrate metabolism/homeostasis) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001072">HP:0001072</a> (Thickened skin) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000956">HP:0000956</a> (Acanthosis nigricans) and <a href="http://purl.obolibrary.org/obo/HP_0003119">HP:0003119</a> (Abnormality of lipid metabolism) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000956">HP:0000956</a> (Acanthosis nigricans) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000819">HP:0000819</a> (Diabetes mellitus) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000818">HP:0000818</a> (Abnormality of the endocrine system) and <a href="http://purl.obolibrary.org/obo/HP_0003077">HP:0003077</a> (Hyperlipidemia) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 76.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003119">HP:0003119</a> (Abnormality of lipid metabolism) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) 74.94%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003119">HP:0003119</a> (Abnormality of lipid metabolism) and <a href="http://purl.obolibrary.org/obo/HP_0009125">HP:0009125</a> (Lipodystrophy) and <a href="http://purl.obolibrary.org/obo/HP_0011121">HP:0011121</a> (Abnormality of skin morphology) 74.94%</li>
</ul>
</body>
</html>
